Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective total hip replacement surgery or a revision of at least one component of a prosthesis implanted ≥ 6 months prior to study entry.~Exclusion Criteria:~* Any major orthopedic surgery in the 3 months prior to study start;~* Deep vein thrombosis or pulmonary embolism within the last 12 months or known post-phlebitic syndrome;~* High risk of bleeding;~* Known allergy to heparin or enoxaparin;~* Any contra-indications to the performance of venography;~* End stage renal disease or patient on dialysis.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semuloparin (Type: EXPERIMENTAL): Semuloparin sodium 20 mg (10 mg if Severe Renal Impairment \[SRI\]) once daily for 7-10 days with an initial dose given 8 hours after surgery~Placebo for Enoxaparin sodium prior to surgery according to local standard for Enoxaparin and 12 hours after surgery to maintain the blind
- Enoxaparin (Type: ACTIVE_COMPARATOR): Enoxaparin sodium 40 mg (20 mg if Severe Renal Impairment \[SRI\]) once daily for 7-10 days with an initial dose given prior to or 12 hours after surgery according to local standard for Enoxaparin sodium~Placebo for Semuloparin sodium 8 hours after surgery to maintain the blind

Based on this trial design, predict the completion outcome and termination type (if applicable).